\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space Digital Europe AI ContinentThe European Commission has published a document to respond to Frequently Asked Questions (FAQs) on the Data Act.
The Data Act, which will become applicable on 12 September 2025, establishes a horizontal set of rules on data access and use that aims to protect fundamental rights and to deliver wide-ranging benefits for the European economy and society. It increases data availability – particularly industrial data – and encourages data-driven innovation while ensuring fairness in the allocation of data value among all actors in the data economy.
It will contribute to the establishment of a single market for data, together with the Data Governance Act, which aims to increase trust in voluntary data-sharing mechanisms.
As applicants to data-related call topics are expected to be aware of relevant EU policies and legislation, these FAQs can provide a useful overview on the Data Act.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The European Cybersecurity Competence Centre (ECCC) has opened a call for tenders to set up a European testing infrastructure for post-quantum cryptography (PQC). Open to applicants across the European Economic Area, the contract is worth EUR 25 million and covers IT services including development and support. The submission deadline is 20 Februa... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
